Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (FRA:FDY)
Germany · Delayed Price · Currency is EUR 0.3420
+0.0020 (0.59%)
At close: Jan 30, 2026
FRA:FDY Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | -62.67 | 39.73 | 108.63 | 138 | 213.3 | 164.66 |
Depreciation & Amortization | 61.41 | 61.41 | 59.93 | 80.97 | 60.85 | 53.61 |
Other Amortization | 20.81 | 20.81 | 2.3 | 1.22 | 0.96 | 1.23 |
Loss (Gain) From Sale of Assets | -0.03 | -0.03 | -0.3 | -1.92 | -1.78 | -4.6 |
Asset Writedown & Restructuring Costs | 4.42 | 4.42 | 5.78 | 1.01 | 0.35 | 0.41 |
Loss (Gain) From Sale of Investments | 10.41 | 10.41 | 4.35 | 1.28 | -20.76 | -17.23 |
Stock-Based Compensation | - | - | -1.84 | 7.69 | 64.97 | - |
Provision & Write-off of Bad Debts | -8.95 | -8.95 | 23.9 | -2.41 | 5.78 | 5.91 |
Other Operating Activities | 271.06 | 2.51 | 6.23 | -0.28 | -6.13 | 12.81 |
Change in Accounts Receivable | 114.05 | 114.05 | -10.47 | -89.73 | -95.37 | -83.54 |
Change in Inventory | -5.86 | -5.86 | -6.57 | -5.84 | 0.32 | -5.41 |
Change in Accounts Payable | -236.31 | -236.31 | -74.05 | 48.72 | 72.56 | -2.54 |
Change in Unearned Revenue | 13.69 | 13.69 | -31.89 | -6.76 | -9.89 | -7.52 |
Operating Cash Flow | 149.63 | -16.51 | 71.02 | 165.27 | 268.9 | 113 |
Operating Cash Flow Growth | 1535.14% | - | -57.03% | -38.54% | 137.96% | -58.03% |
Capital Expenditures | -50.33 | -42.67 | -98.97 | -87.3 | -120.12 | -42.41 |
Sale of Property, Plant & Equipment | 0.75 | 0.64 | 0.68 | 1.44 | 1.71 | 12.03 |
Divestitures | - | - | - | - | 6.34 | - |
Investment in Securities | 18.15 | 18.15 | 52.91 | -10.88 | -243.6 | -16.15 |
Other Investing Activities | 1.45 | 1.74 | - | - | - | - |
Investing Cash Flow | -29.98 | -22.14 | -45.38 | -96.75 | -355.67 | -46.54 |
Short-Term Debt Issued | - | - | - | 101 | - | 51.06 |
Total Debt Issued | - | - | - | 101 | - | 51.06 |
Short-Term Debt Repaid | - | - | - | - | - | -200 |
Long-Term Debt Repaid | - | -7.93 | -109.38 | -9.52 | -7.5 | -5.31 |
Total Debt Repaid | -7.93 | -7.93 | -109.38 | -9.52 | -7.5 | -205.31 |
Net Debt Issued (Repaid) | -7.93 | -7.93 | -109.38 | 91.48 | -7.5 | -154.26 |
Issuance of Common Stock | - | - | 66.86 | - | - | 996.19 |
Repurchase of Common Stock | - | - | - | -8.7 | -40.82 | - |
Common Dividends Paid | -33.26 | -93.29 | -76.15 | -71.04 | -52.15 | -69.77 |
Other Financing Activities | 1.37 | -0.05 | -0.31 | -0.14 | -0.69 | -18.32 |
Financing Cash Flow | -39.82 | -101.27 | -118.98 | 11.61 | -101.16 | 753.85 |
Foreign Exchange Rate Adjustments | 0.28 | 0.32 | -0.07 | 0.29 | -0.07 | -0.22 |
Net Cash Flow | 80.11 | -139.61 | -93.41 | 80.42 | -188.01 | 820.09 |
Free Cash Flow | 99.3 | -59.18 | -27.95 | 77.96 | 148.78 | 70.59 |
Free Cash Flow Growth | - | - | - | -47.60% | 110.76% | -69.15% |
Free Cash Flow Margin | 13.95% | -8.34% | -3.29% | 7.56% | 13.05% | 8.47% |
Free Cash Flow Per Share | 0.12 | -0.06 | -0.03 | 0.08 | 0.14 | 0.07 |
Cash Income Tax Paid | 34.98 | 49.21 | 33.53 | 68.66 | 68.12 | 66.09 |
Levered Free Cash Flow | 75.87 | -96.46 | 18.64 | 86.7 | 116.02 | 33.36 |
Unlevered Free Cash Flow | 76.3 | -96.09 | 20.56 | 87.67 | 116.68 | 36.86 |
Change in Working Capital | -146.83 | -146.83 | -137.96 | -60.29 | -48.63 | -103.8 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.